Cart
sales@molnova.com
Pocenbrodib
CAS No. 2304372-79-8
Pocenbrodib( —— )
Catalog No. M36302 CAS No. 2304372-79-8
Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 1587 | In Stock |
|
| 25MG | 2594 | In Stock |
|
| 50MG | 3143 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePocenbrodib
-
NoteResearch use only, not for human use.
-
Brief DescriptionPocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.
-
DescriptionPocenbrodib (compound II) is a CBP/p300 family of bromodomain inhibitor. Pocenbrodib has the potential for cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2304372-79-8
-
Formula Weight525.57
-
Molecular FormulaC28H32FN3O6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@H](O)(C1=NC2=C(N1[C@H]3C[C@H](C(O)=O)CCC3)C=CC4=C2CC[C@H](C)N4C(OC)=O)C5=C(OC)C=CC(F)=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. George Luke. Inhibiting cyclic amp-responsive element-binding protein (creb). WO2020190780A1.
molnova catalog
related products
-
BRD4-IN-4
BRD4-IN-4 is a selective BRD4 inhibitor with an IC50 value of 6.83 μM for BRD4.BRD4-IN-4 selectively inhibits the proliferation of the MV4-11 cell line and arrests the cells in G1 phase.BRD4-IN-4 can be used to study MLL leukemias.
-
DW71177
DW71177 is a bd1-selective and potent BET inhibitor with potent anti-leukemic activity for the study of leukemia.
-
GSK620
GSK620 is a pan-BD2 inhibitor, which shows an anti-inflammatory phenotype in human whole blood with excellent broad selectivity, developability, and in vivo oral pharmacokinetics.
